JPH0572891B2 - - Google Patents

Info

Publication number: JPH0572891B2
Authority: JP; Japan
Prior art keywords: ester; parts; prepared; acid; drug
Prior art date: 1985-12-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP27559685A

Other languages

English (en)

Japanese (ja)

Other versions

JPS62135435A (ja

Inventor

Naoko Yamanaka

Susumu Sato

Yoko Abe

Mitsuhiko Hori

Shigeyuki Watanabe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nitto Denko Corp

Original Assignee

Nitto Denko Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-12-06

Filing date

1985-12-06

Publication date

1993-10-13

1985-12-06 Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp

1985-12-06 Priority to JP27559685A priority Critical patent/JPS62135435A/ja

1987-06-18 Publication of JPS62135435A publication Critical patent/JPS62135435A/ja

1993-10-13 Publication of JPH0572891B2 publication Critical patent/JPH0572891B2/ja

Status Granted legal-status Critical Current

Links

XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
239000000203 mixture Substances 0.000 claims description 17
125000004432 carbon atom Chemical group C* 0.000 claims description 12
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical class OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 6
125000001931 aliphatic group Chemical group 0.000 claims description 6
239000003960 organic solvent Substances 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 4
-1 n-octyl Chemical group 0.000 description 72
229940079593 drug Drugs 0.000 description 64
239000003814 drug Substances 0.000 description 64
239000002253 acid Substances 0.000 description 31
230000000052 comparative effect Effects 0.000 description 24
239000012153 distilled water Substances 0.000 description 19
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 18
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 18
229960004025 sodium salicylate Drugs 0.000 description 13
238000000034 method Methods 0.000 description 11
125000000217 alkyl group Chemical group 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
235000019441 ethanol Nutrition 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
230000000694 effects Effects 0.000 description 4
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 4
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
210000001015 abdomen Anatomy 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
229960002925 clonidine hydrochloride Drugs 0.000 description 3
239000007788 liquid Substances 0.000 description 3
IRQVJPHZDYMXNW-UHFFFAOYSA-N metoclopramide dihydrochloride monohydrate Chemical compound O.[Cl-].[Cl-].CC[NH+](CC)CCNC(=O)C1=CC(Cl)=C([NH3+])C=C1OC IRQVJPHZDYMXNW-UHFFFAOYSA-N 0.000 description 3
229960000923 metoclopramide hydrochloride Drugs 0.000 description 3
239000004745 nonwoven fabric Substances 0.000 description 3
235000013772 propylene glycol Nutrition 0.000 description 3
239000002904 solvent Substances 0.000 description 3
KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 3
229960005105 terbutaline sulfate Drugs 0.000 description 3
CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 2
SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 2
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000002390 adhesive tape Substances 0.000 description 2
BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
229960001193 diclofenac sodium Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
230000035699 permeability Effects 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 description 1
RRLZLFQAQXYARF-UHFFFAOYSA-N 2-cyclohexylethyl 2-oxopyrrolidine-1-carboxylate Chemical compound C1CCC(=O)N1C(=O)OCCC1CCCCC1 RRLZLFQAQXYARF-UHFFFAOYSA-N 0.000 description 1
XDPIUTURIJYSNO-UHFFFAOYSA-N 2-ethylhexyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCC(CC)COC(=O)N1CCCC1=O XDPIUTURIJYSNO-UHFFFAOYSA-N 0.000 description 1
NPSJHQMIVNJLNN-UHFFFAOYSA-N 2-ethylhexyl 4-nitrobenzoate Chemical compound CCCCC(CC)COC(=O)C1=CC=C([N+]([O-])=O)C=C1 NPSJHQMIVNJLNN-UHFFFAOYSA-N 0.000 description 1
239000004808 2-ethylhexylester Substances 0.000 description 1
ANJAJFJAKLZICO-UHFFFAOYSA-N 2-methylhexyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCC(C)COC(=O)N1CCCC1=O ANJAJFJAKLZICO-UHFFFAOYSA-N 0.000 description 1
HQGWGLASHJVQSJ-UHFFFAOYSA-N 3-cyclopentylpropyl 2-oxopyrrolidine-1-carboxylate Chemical compound C1CCC(=O)N1C(=O)OCCCC1CCCC1 HQGWGLASHJVQSJ-UHFFFAOYSA-N 0.000 description 1
VQSJXSHSUKUYOJ-UHFFFAOYSA-N 4-cyclohexylbutyl 2-oxopyrrolidine-1-carboxylate Chemical compound C1CCC(=O)N1C(=O)OCCCCC1CCCCC1 VQSJXSHSUKUYOJ-UHFFFAOYSA-N 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
ZAILDIWLVUILSE-UHFFFAOYSA-N butyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCOC(=O)N1CCCC1=O ZAILDIWLVUILSE-UHFFFAOYSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
ATKBLOKVJJZAMM-UHFFFAOYSA-N cycloheptyl 2-oxopyrrolidine-1-carboxylate Chemical compound C1CCC(=O)N1C(=O)OC1CCCCCC1 ATKBLOKVJJZAMM-UHFFFAOYSA-N 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
JZPSPVYZFXNNRK-UHFFFAOYSA-N cyclohexylmethyl 2-oxopyrrolidine-1-carboxylate Chemical compound C1CCC(=O)N1C(=O)OCC1CCCCC1 JZPSPVYZFXNNRK-UHFFFAOYSA-N 0.000 description 1
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
AUTNUBIPSVJOIK-UHFFFAOYSA-N cyclooctyl 2-oxopyrrolidine-1-carboxylate Chemical compound C1CCC(=O)N1C(=O)OC1CCCCCCC1 AUTNUBIPSVJOIK-UHFFFAOYSA-N 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
SSUXCXWKHBHFEH-UHFFFAOYSA-N decyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCCCCCCCOC(=O)N1CCCC1=O SSUXCXWKHBHFEH-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
OPUNQOCLIVUKMO-UHFFFAOYSA-N dodecyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCCCCCCCCCOC(=O)N1CCCC1=O OPUNQOCLIVUKMO-UHFFFAOYSA-N 0.000 description 1
230000005611 electricity Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
ZSUZUJSDKZPWHH-UHFFFAOYSA-N ethyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCOC(=O)N1CCCC1=O ZSUZUJSDKZPWHH-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
IFGPXDKTPZGTSC-UHFFFAOYSA-N heptyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCCCCOC(=O)N1CCCC1=O IFGPXDKTPZGTSC-UHFFFAOYSA-N 0.000 description 1
VROJYRWXSALTFL-UHFFFAOYSA-N hexadecyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCCCCCCCCCCCCCOC(=O)N1CCCC1=O VROJYRWXSALTFL-UHFFFAOYSA-N 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
SMMMXPNNEVLBRH-UHFFFAOYSA-N icosyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCCCCCCCCCCCCCCCCCOC(=O)N1CCCC1=O SMMMXPNNEVLBRH-UHFFFAOYSA-N 0.000 description 1
YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229940035429 isobutyl alcohol Drugs 0.000 description 1
229960004592 isopropanol Drugs 0.000 description 1
125000005645 linoleyl group Chemical group 0.000 description 1
230000007774 longterm Effects 0.000 description 1
WFYCWAPHNCARGR-UHFFFAOYSA-N methyl 2-oxopyrrolidine-1-carboxylate Chemical compound COC(=O)N1CCCC1=O WFYCWAPHNCARGR-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
ZCOGQSHZVSZAHH-UHFFFAOYSA-N n,n-dimethylaziridine-1-carboxamide Chemical compound CN(C)C(=O)N1CC1 ZCOGQSHZVSZAHH-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
BNMGHTMPTXZOHA-UHFFFAOYSA-N nonan-2-yl 2-oxopyrrolidine-1-carboxylate Chemical class CCCCCCCC(C)OC(=O)N1CCCC1=O BNMGHTMPTXZOHA-UHFFFAOYSA-N 0.000 description 1
GYEIHWMOVAIDAD-UHFFFAOYSA-N nonyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCCCCCCOC(=O)N1CCCC1=O GYEIHWMOVAIDAD-UHFFFAOYSA-N 0.000 description 1
QYVZEPLDLPYECM-XUTLUUPISA-N octadecyl (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C1=CC=C(O)C(O)=C1 QYVZEPLDLPYECM-XUTLUUPISA-N 0.000 description 1
NWKNKIKNQBSFGH-UHFFFAOYSA-N octadecyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)N1CCCC1=O NWKNKIKNQBSFGH-UHFFFAOYSA-N 0.000 description 1
WTJUYBSTYYKTGD-UHFFFAOYSA-N octyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCCCCCOC(=O)N1CCCC1=O WTJUYBSTYYKTGD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
239000012466 permeate Substances 0.000 description 1
229920000166 polytrimethylene carbonate Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
YTLHAWKUXSUXIR-UHFFFAOYSA-N propyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCOC(=O)N1CCCC1=O YTLHAWKUXSUXIR-UHFFFAOYSA-N 0.000 description 1
229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000037384 skin absorption Effects 0.000 description 1
231100000274 skin absorption Toxicity 0.000 description 1
238000003756 stirring Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
KUKAXYLECOULLV-UHFFFAOYSA-N tetradecyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCCCCCCCCCCCOC(=O)N1CCCC1=O KUKAXYLECOULLV-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
SAGFKEVKFWCOPZ-UHFFFAOYSA-N tridecyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCCCCCCCCCCOC(=O)N1CCCC1=O SAGFKEVKFWCOPZ-UHFFFAOYSA-N 0.000 description 1
FDDOEWMEOHASSD-UHFFFAOYSA-N undecyl 2-oxopyrrolidine-1-carboxylate Chemical compound CCCCCCCCCCCOC(=O)N1CCCC1=O FDDOEWMEOHASSD-UHFFFAOYSA-N 0.000 description 1
229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Landscapes

Medicinal Preparation (AREA)

JP27559685A 1985-12-06 1985-12-06 イオントフオレ−ゼ生体電極用基剤組成物 Granted JPS62135435A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP27559685A JPS62135435A (ja)	1985-12-06	1985-12-06	イオントフオレ−ゼ生体電極用基剤組成物

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP27559685A JPS62135435A (ja)	1985-12-06	1985-12-06	イオントフオレ−ゼ生体電極用基剤組成物

Publications (2)

Publication Number	Publication Date
JPS62135435A JPS62135435A (ja)	1987-06-18
JPH0572891B2 true JPH0572891B2 (de)	1993-10-13

Family

ID=17557647

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP27559685A Granted JPS62135435A (ja)	1985-12-06	1985-12-06	イオントフオレ−ゼ生体電極用基剤組成物

Country Status (1)

Country	Link
JP (1)	JPS62135435A (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1095681C (zh) *	1996-06-20	2002-12-11	久光制药株式会社	一种用于离子电渗疗法的装置结构

1985
- 1985-12-06 JP JP27559685A patent/JPS62135435A/ja active Granted

Also Published As

Publication number	Publication date
JPS62135435A (ja)	1987-06-18

Publication	Publication Date	Title
CN101801359B (zh)	2013-11-06	确保有效成分经生物界面增加释放的透皮递送设备
US6673363B2 (en)	2004-01-06	Transdermal and topical administration of local anesthetic agents using basic enhancers
US5130139A (en)	1992-07-14	Reduction or prevention of skin irritation by drugs
CN102458397A (zh)	2012-05-16	特别是用于电离子透入疗法的、含有罗替戈汀盐（酸或na）的药物组合物
US6643544B1 (en)	2003-11-04	Iontophoresis device
US7795309B2 (en)	2010-09-14	Topical formulation including diclofenac, or a pharmaceutically acceptable salt thereof
EP0164998A2 (de)	1985-12-18	Mittel und Verfahren zur Erhöhung der transdermalen und transmembranen Penetration topischer und systemischer Wirkstoffe
US20020192243A1 (en)	2002-12-19	Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
HK1201763A1 (en)	2015-09-11	Polyamine enhanced formulations for triptan compound iontophoresis
US6183771B1 (en)	2001-02-06	Transdermal compositions containing levosimendan
US5160741A (en)	1992-11-03	Reduction or prevention of skin irritation by drugs
JPH0572891B2 (de)	1993-10-13
EP3939564B1 (de)	2024-10-09	Kataplasmapflaster zur linderung von topischen schmerzen
JPH0572890B2 (de)	1993-10-13
CA3086494A1 (en)	2019-06-27	Frigostable composition for iontophoretic transdermal delivery of a triptan compound
US6521613B2 (en)	2003-02-18	Lactam compounds for penetration enhancement
JPH0480706B2 (de)	1992-12-21
JP2001072605A (ja)	2001-03-21	経皮経粘膜吸収促進剤組成物
US20150297718A1 (en)	2015-10-22	Iontophoresis delivery of cationic prodrugs for topical treatment of musculoskeletal or skin diseases
JPS6299333A (ja)	1987-05-08	イオントフオレ−ゼ生体電極用基剤組成物
JPS6131169A (ja)	1986-02-13	イオントフォレ−ゼ用デバイス
JPS61260027A (ja)	1986-11-18	経皮吸収性を高めた皮膚外用剤
US20080221212A1 (en)	2008-09-11	Topical formulation
EP0309624A1 (de)	1989-04-05	Mittel zur Verbesserung der perkutanen Verabreichung von Arzneimitteln
JPWO2000061218A1 (ja)	2002-07-16	イオントフォレーシスデバイス及び通電方法